Profitable companies and non-Profitable Biotech companies (rising stars) have developed innovative drugs for treatment of chronic and non chronic diseases. In the next five years the distinction between mature biotech companies and large global pharma is likely to disappear as investment in R&D and acquisition start delivering and Market Cap match the large global pharma. Dividend and consolidation could be the future drivers and continue to attract long term investors. Optimism prevails around the future of this sector as a whole which was reflected in the unprecedented rally in shares in 2012.
This trend continued in the next five years driven by launch of Innovative drugs catering to unmet needs in Alzheimer’s, HCV, osteoporosis, RA, Psoriasis, MS, Dyslipidemia, Cystic fibrosis, Cancer and orphan diseases. Drug approvals and label expansion of existing portfolio of launched drugs and data from late stage pipeline drugs should maintain the growth momentum and investors interest.
The early part of the previous decade (2010-20) was spent recovering from the big acquisitions made by this sector but followed by the exercising of some restrain for similar large acquisitions as investors wanted to see the returns reflected in the top-line and EPS. However in- licensing of early or mid stage compounds or small acquisitions continued since the Rising Stars kept throwing the bait by taking risks and innovate using novel technology platforms or validating novel targets for treating diseases.
Patent expiry impact was also modest as majority had “not so easy to copy” biologics and other drugs in their portfolio. They, however were not complacent and were not leaving any stones unturned to meet the challenges as well as exploring emerging market opportunities with local partners. Favorable regulatory environment finally saw biosimilar mAbs entry in regulated markets The optimism of biosimilar players is reflected in the maturing pipeline. Para IV Filing from other generic players continues to pour leaving room for surprises and volatility.
Moving forward the sector should see a strategic rise of the digital mindset and further adoption of transformative and augumentative technologies. While mergers & acquisitions can still expect a sharper focus despite being more traditional, external innovation should result in a meaningful shift in culture through innovative and creative partnerships with both new entrants and less traditional companies.
There will be an increasing demand for even more transparency and disclosure and a need for real relationship-driven partnerships will encroach across all sector stakeholders including regulators, patients, advocacy groups and also to outsourcing players critical to the supply chain. Data will be a dominating force behind new revenue models and crucial to understanding and delivering an exceptional patient experience. Pricing will continue to exert much pressure, increasing access to drugs, growth of gene and cell therapies, and uncertain trade policies will further change the dynamics of the market.
Industry News
- Assessing Resilience and Care Skills in Oncology Nursesby Bioengineer on October 19, 2025 at 10:58 am
In the contemporary healthcare landscape, the importance of psychological resilience among oncology nurses cannot be overstated. The role of these healthcare professionals extends far beyond administering treatments; they are pivotal in providing emotional support to patients grappling with cancer. In a groundbreaking cross-sectional study led by Özcan, Özkaraman, and Özgenel, the authors delve into the
- Exploring Chronic Hepatitis B and Fatty Liver Proteomicsby Bioengineer on October 19, 2025 at 10:52 am
Chronic hepatitis B virus (HBV) infection remains a leading cause of liver-related morbidity and mortality worldwide. Recent advancements in proteomics have opened new avenues for understanding the intricate biological interactions between HBV and non-alcoholic fatty liver disease (NAFLD), a condition increasingly recognized as pivotal in shaping liver disease profiles among patients with chronic hepatitis. A
- New Distribution Record: Cymbalaria muralis in Kashmir Himalayaby Bioengineer on October 19, 2025 at 10:18 am
In a remarkable stride toward biodiversity understanding, the discovery of Cymbalaria muralis (commonly known as wall pennywort) in the Kashmir Himalaya marks a significant academic achievement, as reported in a recent publication in the journal Discover Plants. This chasmophyte, belonging to the Plantaginaceae family, has been overlooked in this region until now. The research team,
- Pyrroloquinoline Quinone Alleviates Spinal Pain in Miceby Bioengineer on October 19, 2025 at 9:52 am
In a groundbreaking study, researchers have identified a novel therapeutic application for Pyrroloquinoline quinone (PQQ), a naturally occurring compound known for its antioxidant properties. The research team, led by Geng et al., focused on the implications of PQQ for addressing the challenges posed by senescent osteoclasts—cells that are pivotal in bone resorption and frequently implicated
- New Drug Combination Reduces Mortality Risk in Advanced Prostate Cancer by 40%by Bioengineer on October 19, 2025 at 9:17 am
A groundbreaking advancement in prostate cancer treatment offers new hope to men whose disease returns after initial attempts at surgery or radiation therapy. The latest clinical trials unveil a powerful new drug regimen capable of drastically reducing mortality risk, marking a significant milestone in the battle against high-risk biochemically recurrent prostate cancer. For decades, the
- AI Enhances Non-Invasive Sleep Stage Detectionby Bioengineer on October 19, 2025 at 8:11 am
In an era where sleep is increasingly recognized for its pivotal role in overall health and well-being, researchers are striving to enhance understanding and monitoring of sleep processes. The landmark study led by Aktaruzzaman and Everett encapsulates this initiative through the development of an advanced, non-invasive methodology for detecting sleep stages. Their research uniquely merges
- Sex Differences in Energy Demand in Alzheimer’s Modelby Bioengineer on October 19, 2025 at 8:00 am
A groundbreaking study published in “Biology of Sex Differences” highlights the intricate dynamics of energy demand variations between male and female subjects during the preplaque stage of Alzheimer’s disease, utilizing a transgenic mouse model that mirrors human Alzheimer’s pathology. This pivotal research led by a team of scientists, including Ren Sun, Lisa K. Zimbalski, and
- Antibody-Drug Conjugates Enhance Outcomes in Advanced Triple-Negative Breast Cancer Patients Unsuitable for Immune Checkpoint Inhibitorsby Bioengineer on October 19, 2025 at 7:21 am
In a groundbreaking advancement in the treatment of aggressive breast cancers, researchers have unveiled promising results from the ASCENT-03 trial, identifying sacituzumab govitecan as a transformative therapy for patients battling triple-negative breast cancer (TNBC) who are unsuitable candidates for immune checkpoint inhibitor therapy. This compelling evidence, emerging from a global phase 3 clinical study led
- Insights on Autistic Employees in Competitive Employmentby Bioengineer on October 19, 2025 at 7:02 am
In recent years, the integration of autistic individuals into the workforce has garnered increasing attention from researchers, employers, and advocates alike. A notable study led by Athamanah, White, and Frala, published in the Journal of Autism and Developmental Disorders, examines the experiences of employers who have hired autistic employees in competitive integrated employment settings. This
- Novice Nurses’ Role in Workplace Adaptation: Study Insightsby Bioengineer on October 19, 2025 at 6:02 am
In the realm of healthcare, the transition from academia to a professional setting can often be formidable, particularly for novice nurses. The intricacies of workplace culture, expectations, and the demand for adaptability can pose substantial challenges. A cross-sectional study conducted by Y. Nagano and Y. Hosoda sheds light on a critical yet often understated aspect
- Revealing Aging Changes in Renal Tubulointerstitiumby Bioengineer on October 19, 2025 at 5:44 am
Recent advancements in spatial proteomics have opened new avenues for understanding the biological mechanisms behind aging, particularly in the renal tubulointerstitium—a crucial component of the kidney. Researchers have embarked on a groundbreaking study that reveals how aging leads to significant alterations in this region, which is vital for maintaining renal function and overall health. By
- Reversing Cellular Aging: PURPL RNA’s Epigenetic Breakthroughby Bioengineer on October 19, 2025 at 4:50 am
Recent advancements in cellular biology have illuminated the transformative potential of targeting specific RNA molecules to rejuvenate senescent cells. In a groundbreaking study, researchers led by Wang et al. have explored the roles of PURPL RNA in reprogramming senescent cells through epigenetic mechanisms. Their findings, published in the Journal of Translational Medicine, suggest that manipulating
- Restoring Kraak Porcelain Patterns with Generative AIby Bioengineer on October 19, 2025 at 3:10 am
In a transformative study published in Scientific Reports, researchers have embarked on an ambitious project to restore and generate intricate Kraak porcelain decorative patterns using advanced generative artificial intelligence techniques. Kraak porcelain, known for its exquisite craftsmanship and rich history, has captivated art lovers and collectors for centuries. The study revolves around the development of
- Sex Differences in Anxiety and Depression Modulationby Bioengineer on October 19, 2025 at 2:59 am
Recent advances in neuroscience have illuminated the intricate relationships between genetic expression, behavior, and emotional health. One particularly compelling study, authored by Senserrich et al., has delved deeply into the sex differences influencing anxiety and depression-like behaviors, centering its focus on a key player in the neurobiological landscape: matrix metalloproteinase-9 (MMP-9). This enzyme, known for
- Exploring Language Switching in Multilingual Autistic Adultsby Bioengineer on October 19, 2025 at 2:01 am
In a groundbreaking study, researchers have delved into the intricacies of language switching behaviors among multilingual autistic and non-autistic adults. The exploration, conducted by Crockford, Gibson, and Katsos, uncovers critical insights into how these two groups navigate their linguistic environments. Parallels drawn in this research could have profound implications for our understanding of cognitive processing
- Effective Nursing Strategies for Cardiovascular Disease Preventionby Bioengineer on October 19, 2025 at 1:01 am
Nursing interventions are of paramount importance in the continuous battle against cardiovascular disease (CVD), a leading cause of mortality globally. The recent narrative review conducted by Garea and Díaz sheds light on evidence-based strategies that nurses can implement to mitigate the risk of cardiovascular complications. This comprehensive exploration into nursing interventions is more than just
- Serum Proteomics: Uncovering COVID-19 Organ Morbidity Biomarkersby Bioengineer on October 19, 2025 at 12:48 am
In a groundbreaking study set to reshape our understanding of the intricate relationship between COVID-19 and its long-term consequences, a team of researchers led by M.V. Rajan, V. Sharma, and N. Upadhyay has unveiled compelling data derived from serum proteomics. This innovative approach looks beyond the immediate viral threat posed by SARS-CoV-2 to identify biomarkers
- ARNT2 Activates STRA6, Fueling Liposarcoma Progressionby Bioengineer on October 19, 2025 at 12:37 am
Recent research has unveiled critical insights into the biological mechanisms underlying retroperitoneal liposarcoma (RPLS), a rare and aggressive form of cancer originating from fat tissue in the retroperitoneum. In a pioneering study conducted by Zhang et al., it has been demonstrated that the aryl hydrocarbon receptor nuclear translocator 2 (ARNT2) plays a significant role in
- Diabetes Management Linked to Social Vulnerability Factorsby Bioengineer on October 19, 2025 at 12:30 am
In the realm of public health, the interplay between chronic disease management and social factors has garnered significant attention in recent years. A pivotal study titled “Association Between Diabetes Management Behaviors and State-Level Social Vulnerability: A Cross-sectional Study,” recently brought to light the complex intersection of diabetes management and social vulnerability. In a world where
- Predicting Neoantigens for Cancer Immunotherapy Advancesby Bioengineer on October 19, 2025 at 12:18 am
Cancer remains one of the most formidable challenges in global health, claiming millions of lives annually and placing immense strain on healthcare systems worldwide. The disease’s complexity is deeply rooted in its genetic basis, where mutations and alterations at various molecular levels result in malignant transformation. Among the most promising avenues for combating cancer is
- ESMO: AstraZeneca believes latest data 'validate' going it alone on next-gen ADCson October 18, 2025 at 10:57 am
Europe’s leading cancer conference may be swimming in ADC data, but AstraZeneca remains convinced its in-house pipeline sets the pharma apart.
- ESMO: Tubulis’ next-gen ADC posts 59% response rate, justifying investor intereston October 18, 2025 at 8:33 am
Tubulis’ next-generation ADC has been tied to an overall response rate of 59% as the German biotech tastes its first clinical success.
- Xoma and Lava buyout cools with lower cash offer and closing conditionson October 17, 2025 at 2:38 pm
Xoma Royalty and Lava Therapeutics are turning the temperature down, dropping both the cash per share offer and closing cash conditions for an acquisition inked back in August.
- NLS Days: How do things look for biotech in Sweden? by Jules Adam on October 17, 2025 at 1:00 pm
As Labiotech attented the NLS Days this week, it was the occasion to learn more about the biotech industry in Sweden. The post NLS Days: How do things look for biotech in Sweden? appeared first on Labiotech.eu. © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Labiotech UG and Labiotech.eu with appropriate and specific direction to the original content.
- ESMO: Pfizer sees year-long weight gain in cancer patients with wasting conditionon October 17, 2025 at 11:09 am
For the second year running, Pfizer has arrived at the European Society for Medical Oncology (ESMO) conference armed with data showing its one-time heart failure hopeful ponsegromab can treat a wasting syndrome.
- ESMO: Evaxion hopes cancer vax data attract partner after cash crunch forces smaller phase 2 trialon October 17, 2025 at 11:08 am
Danish vaccine developer Evaxion has released long-term data for its lead personalized cancer vaccine, with the shot scoring a 75% objective response rate (ORR) in patients with advanced melanoma after two years. But the trial enrolled far fewer patients than originally planned and did not evaluate its primary endpoint.
- ESMO: Roche wants oral SERD to benefit 'all comers,' unveils phase 3 breast cancer dataon October 17, 2025 at 10:39 am
Roche’s giredestrant was shown to reduce the risk of breast cancer progression or death by 62% in a specific cohort of a phase 3 trial.
- Astellas walks away from gene therapy pact with Taysha before pivotal trial launchon October 17, 2025 at 10:24 am
For the second time, Astellas is walking away from Taysha Gene Therapies, this time choosing not to license the biotech’s adeno-associated-virus-based therapy designed to treat a rare neurodevelopmental condition.
- I-Mab undergoes makeover, with new name, strategy, asset and Hong Kong IPO planson October 17, 2025 at 10:17 am
Less than two years after laying out plans to divest its China operations and become a U.S.-focused biotech, I-Mab Biopharma is re-staking its claim in the Asia-Pacific region.
- Licensing galore: Roche ties up with Hansoh on ADCs as Rani rounds out week with Chugai pacton October 17, 2025 at 9:58 am
Hansoh has announced a deal with Roche worth up to $1.45 billion biobucks to grant the Swiss drugmaker a global license to develop, manufacture and sell its experimental ADC. At the same time, Rani has secured an agreement worth up to $1.09 billion to wed its drug delivery tech with Chugai's antibody assets in rare disease.
- Unpacking the FDA transparency push on CRLsby , on October 17, 2025 at 9:41 am
The FDA made waves in early September when it announced a plan to publicly release complete response letters, or CRLs, at the same time they are issued to sponsoring companies. What risks and opportunities does this new policy pose for biopharma companies?
- ESMO: BMS looks to 'stay ahead of the competition' with ADC's 55% response rate in early-stage trialon October 17, 2025 at 9:37 am
Bristol Myers Squibb touted a 55% overall response rate from one cohort of an early-stage study of its EGFRxHER3 antibody-drug conjugate.
- Biotech royalty deals on the rise and here to stayby Dylan Kissane on October 17, 2025 at 8:00 am
In today's episode, we welcome Clarke Futch, Chairman and CEO of HealthCare Royalty Partners, or HCRx, with a thirty year track record in biopharma investing. The post Biotech royalty deals on the rise and here to stay appeared first on Labiotech.eu. © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Labiotech UG and Labiotech.eu with appropriate and specific direction to the original content.
- Kezar plans layoffs after FDA cancels meeting to discuss next trialon October 17, 2025 at 4:54 am
The FDA’s cancellation of a meeting to discuss the next steps in a R&D program has prompted Kezar Life Sciences to prepare to lay off staff and explore strategic alternatives.
- FDA names 9 first recipients of 1- to 2-month priority review voucherson October 17, 2025 at 4:50 am
The FDA has handed out the first nine national priority vouchers, positioning companies including Merck KGaA, Regeneron and Sanofi to complete the approval process in one to two months.
- Kite puts $1.6B on the line to pair up with China's Pregene for another in vivo CAR-T dealon October 16, 2025 at 4:57 pm
Gilead’s Kite Pharma is doubling down on in vivo CAR-T, this time inking a deal worth up to $1.64 billion biobucks with Chinese biotech Pregene Biopharma.
- Chutes & Ladders—Cabaletta corrals cell therapy Legend as commercial chiefby , on October 16, 2025 at 4:14 pm
Just a few months after surfacing at Orca Bio following his early 2025 departure from Legend Biotech, Steve Gavel has taken on the chief commercial officer role at yet another cell therapy biotech. He is now CCO at Cabaletta Bio, effective immediately, where he brings a wealth of cell therapy experience.
- Praxis erases doubts with phase 3 wins in essential tremor, sending shares soaringon October 16, 2025 at 11:08 am
The trials demonstrated the benefits of Praxis' ulixacaltamide in essential tremor after a previously grim outlook at an interim analysis of one of the studies earlier this year.
- French antibody biotech draws in $122M for end-of-year clinical pushon October 16, 2025 at 10:59 am
French antibody specialist Adcytherix has added a €105 million ($122 million) series A to its coffers, which the Marseille-based biotech will use to push its lead antibody-drug conjugate into clinical trials.
- Dianthus offers up to $1B for China biotech's autoimmune 'pipeline in a product'on October 16, 2025 at 10:26 am
Dianthus Therapeutics is offering Nanjing Leads Biolabs up to $1 billion biobucks for licensing rights to a bifunctional fusion protein designed to treat certain autoimmune disorders.
- Sanofi inks $500M deal with Evoq for next-gen autoimmune techon October 16, 2025 at 9:40 am
University of Michigan spinout Evoq Therapeutics has struck its third major partnership with a biopharma powerhouse, signing on with Sanofi in a deal worth up to $500 million. The agreement comes after Evoq entered deals with Gilead Sciences in 2023 and Amgen in 2021.
- AstraZeneca pens fresh IBD collab with long-term AI partner Immunai worth $85Mon October 16, 2025 at 3:51 am
AstraZeneca has returned to its longtime AI partner Immunai with a new deal worth up to $85 million to advance a target for a new inflammatory bowel disease therapy.
- 'We can have TikTok. Why can’t we have drugs?': Nkarta CEO Paul Hastings warns against China biotech penaltieson October 15, 2025 at 4:49 pm
As geopolitical tensions rise, Nkarta CEO Paul Hastings is urging the U.S. government not to impose restrictions on Chinese scientific collaboration and refocus on what matters most: the patient.
- Biotech in Luxembourg: five companies that have made their nameby Roohi Mariam Peter on October 15, 2025 at 1:00 pm
As the biotech industry in Luxembourg gradually grows, let us take a look at five biotech companies that are flourishing in the field. The post Biotech in Luxembourg: five companies that have made their name appeared first on Labiotech.eu. © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Labiotech UG and Labiotech.eu with appropriate and specific direction to the original content.
- Boehringer Ingelheim digs in on ADCs, offering up to $991M to license cancer prospect from Korea's AimedBioon October 15, 2025 at 9:42 am
Boehringer Ingelheim will pay AimedBio up to $991 million to license and develop one of the South Korean biotech’s antibody-drug conjugates across a “broad range of cancers." The ADC asset girding the deal targets a protein expressed in many malignancies that plays a “significant role” in tumor growth, metastasis and therapeutic resistance, the partners said.
- The advent of AI for peptide design: An emerging fieldby Willow Shah-Neville on October 15, 2025 at 8:29 am
Discover the emerging field of AI-based peptide discovery and design – could this signal the beginning of a golden age for peptides? The post The advent of AI for peptide design: An emerging field appeared first on Labiotech.eu. © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Labiotech UG and Labiotech.eu with appropriate and specific direction to the original content.
- Aicuris antiviral scores in phase 3 HSV trial, setting up FDA filingon October 14, 2025 at 4:56 pm
Aicuris has reported the success of a phase 3 trial, which has demonstrated the superiority of oral antiviral pritelivir compared to standard-of-care treatments in healing lesions of immunocompromised patients with refractory HSV infections. The study paves the way for an FDA new drug application, the German company said on Wednesday.
- Prader Willi syndrome: five much-anticipated therapies poised for approval by Roohi Mariam Peter on October 14, 2025 at 1:04 pm
The treatment drug to address insatiable hunger in people with Prader-Willi syndrome was greenlit this year. Discover five therapies in line for approval. The post Prader Willi syndrome: five much-anticipated therapies poised for approval appeared first on Labiotech.eu. © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Labiotech UG and Labiotech.eu with appropriate and specific direction to the original content.
- Cambridge’s biotech scene: The cornerstone of the UK’s Golden Triangleby Willow Shah-Neville on October 13, 2025 at 1:00 pm
Home to a well-established hub with strong investment and startup activity, discover what makes Cambridge's biotech scene so special. The post Cambridge’s biotech scene: The cornerstone of the UK’s Golden Triangle appeared first on Labiotech.eu. © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Labiotech UG and Labiotech.eu with appropriate and specific direction to the original content.
- Practical partnering at BIOSPAIN: on the ground with biotech innovators ready to take the next stepby Dylan Kissane on October 10, 2025 at 1:00 pm
We were on the ground in Barcelona speaking to biotech companies, university technology transfer offices, and top pharma firms about their experience at BIOSPAIN and their progress towards securing partnerships. The post Practical partnering at BIOSPAIN: on the ground with biotech innovators ready to take the next step appeared first on Labiotech.eu. © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Labiotech UG and Labiotech.eu with appropriate and specific direction to the original content.
- Contraline’s ADAM in the clinic: towards a new era of male contraception?by Dylan Kissane on October 10, 2025 at 8:00 am
In this week's podcast we talked with Kevin Eisenfrats, CEO of Contraline, about contraception, male contraception. The post Contraline’s ADAM in the clinic: towards a new era of male contraception? appeared first on Labiotech.eu. © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Labiotech UG and Labiotech.eu with appropriate and specific direction to the original content.
- Are European biotech VCs under pressure to scale? Time to get pragmatic by Jules Adam on October 9, 2025 at 1:00 pm
As Asabys Partners has rolled Aliath Bioventures into its platform, it's worth asking if European biotech VCs are under pressure to scale. The post Are European biotech VCs under pressure to scale? Time to get pragmatic appeared first on Labiotech.eu. © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Labiotech UG and Labiotech.eu with appropriate and specific direction to the original content.
- Top biotech deals in September 2025 by Roohi Mariam Peter on October 8, 2025 at 8:00 am
Discover the top biotech deals of September 2025, as four billion-dollar acquisitions took place and several licensing deals were signed. The post Top biotech deals in September 2025 appeared first on Labiotech.eu. © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Labiotech UG and Labiotech.eu with appropriate and specific direction to the original content.
- Six companies leading the mRNA revolution in biotechnologyby Roohi Mariam Peter on October 7, 2025 at 1:00 pm
Here are six mRNA biotechs that have raised funds in recent years to push their candidates ahead through preclinical and clinical trials. The post Six companies leading the mRNA revolution in biotechnology appeared first on Labiotech.eu. © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Labiotech UG and Labiotech.eu with appropriate and specific direction to the original content.
- AKIGAI takes EGFR inhibitors beyond cancer to treat neuropathic pain by Jules Adam on October 7, 2025 at 8:19 am
Discover how AKIGAI’s EGFR inhibitors may redefine neuropathic pain therapy and offer hope for complex regional pain syndrome (CRPS). The post AKIGAI takes EGFR inhibitors beyond cancer to treat neuropathic pain appeared first on Labiotech.eu. © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Labiotech UG and Labiotech.eu with appropriate and specific direction to the original content.
- Protecting Your Drug Patent in Global Markets: Strategies and Challengesby Insights: DrugPatentWatch - Find Your Next Blockbuster on February 27, 2025 at 9:19 am
Navigating the Complex World of Global Drug Patents: Strategies and Challenges Ahead As a pharmaceutical professional, you know how crucial it is to protect your innovative drug patents in the global market. With the rise of international trade and the... Source
- Drafting Drug Patent Applications for Biologic Drugsby Insights: DrugPatentWatch - Find Your Next Blockbuster on February 26, 2025 at 11:45 am
The Complex World of Biologic Drugs: Navigating Patent Applications As a biotech professional, you're likely no stranger to the intricacies of developing life-saving treatments. But when it comes to biologic drugs, the process can be particularly chall... Source
- Successfully Patenting Drug Combinations: Strategies and Challengesby Insights: DrugPatentWatch - Find Your Next Blockbuster on February 26, 2025 at 9:57 am
Unlocking the Power of Combination Therapies: Strategies for Successful Patenting As a pharmaceutical professional, you know that combination therapies have revolutionized the treatment of complex diseases. By pairing two or more active ingredients, yo... Source
- Effective Strategies for Generic Drug Price Settingby Insights: DrugPatentWatch - Find Your Next Blockbuster on February 25, 2025 at 9:17 am
The Secret to Setting the Right Price for Your Generic Medications As a generic drug manufacturer, you're constantly looking for ways to stay ahead of the competition and bring affordable medications to market. But have you ever wondered how to set the... Source
- Optimizing the Generic Drug Supply Chain: Strategies for Successby Insights: DrugPatentWatch - Find Your Next Blockbuster on February 24, 2025 at 11:56 pm
Unlocking Efficiency in the Generic Drug Supply Chain As the pharmaceutical industry continues to evolve, the generic drug supply chain has become a critical component of ensuring timely and affordable access to life-saving medications. However, naviga... Source
- FDA Updates: What Do the Latest Changes Mean for Generic Drug Approval?by Insights: DrugPatentWatch - Find Your Next Blockbuster on February 24, 2025 at 8:55 pm
Breaking News: FDA Updates - What Do the Latest Changes Mean for Generic Drug Approval? As a healthcare professional or a business leader in the pharmaceutical industry, you're likely aware of the complex landscape surrounding generic drug approval. Re... Source
- Regulatory Challenges in the Latin American Generic Drug Marketby Insights: DrugPatentWatch - Find Your Next Blockbuster on February 24, 2025 at 4:10 pm
Breaking Down Barriers: Navigating Regulatory Challenges in Latin America's Generic Drug Market As the demand for affordable generic medications continues to grow, Latin America has emerged as a critical region for pharmaceutical companies looking to e... Source
- Analyzing the cost-effectiveness of biosimilars in different healthcare systemsby Insights: DrugPatentWatch - Find Your Next Blockbuster on February 23, 2025 at 11:27 am
The Future of Affordable Healthcare: Can Biosimilars Deliver? As healthcare professionals, we're constantly on the lookout for innovative solutions to improve patient outcomes while reducing costs. One promising approach is the use of biosimilars – bio... Source
- How to Achieve High-Quality Standards in Generic Drugsby Insights: DrugPatentWatch - Find Your Next Blockbuster on February 20, 2025 at 11:21 am
Ensuring the Highest Quality in Generic Medications: A Crucial Step in Healthcare As the global demand for affordable healthcare continues to rise, generic medications have become a vital lifeline for millions of people worldwide. However, with the inc... Source
- The Role of Quality Assurance in Generic Drugsby Insights: DrugPatentWatch - Find Your Next Blockbuster on February 19, 2025 at 11:07 am
The Unseen Heroes of Generic Medicines: The Crucial Role of Quality Assurance As we navigate the complex world of pharmaceuticals, it's easy to overlook the unsung heroes behind the scenes. But today, I want to shine a spotlight on the Quality Assuranc... Source
- DrugChatter: Can lurbinectedin treat ovarian cancer?by DrugChatter on February 19, 2025 at 6:44 am
Can Lurbinectedin Treat Ovarian Cancer? A Comprehensive Review Ovarian cancer is a devastating disease that affects thousands... https://www.Drugchatter.com/chat/25460/can-lurbinectedin-treat-ovarian-cancer/ Source
- Regulatory considerations for biosimilar clinical efficacy trialsby Insights: DrugPatentWatch - Find Your Next Blockbuster on February 18, 2025 at 3:27 pm
Unlocking the Potential of Biosimilars: Navigating Regulatory Considerations for Clinical Efficacy Trials As the pharmaceutical industry continues to evolve, biosimilars have emerged as a game-changer in the quest for affordable and accessible treatmen... Source
- The basics of drug patent searchingby Insights: DrugPatentWatch - Find Your Next Blockbuster on February 18, 2025 at 10:38 am
Unlock the Secrets of Drug Patent Searching: A Beginner's Guide As a professional in the pharmaceutical industry, staying ahead of the curve is crucial. One of the most critical aspects of this is understanding the world of drug patents. But have you e... Source
- Navigating the Generic Drug Approval Process: A Comprehensive Guideby Insights: DrugPatentWatch - Find Your Next Blockbuster on February 17, 2025 at 10:33 am
Unlocking the Path to Generic Medication Approval: A Step-by-Step Guide As a healthcare professional or a business leader in the pharmaceutical industry, you're likely aware of the complex landscape surrounding generic medication approval. With the eve... Source
- Strategies for successful biosimilar-to-biosimilar switchingby Insights: DrugPatentWatch - Find Your Next Blockbuster on February 16, 2025 at 4:04 pm
The Future of Biosimilars: Switching Strategies for Success As the biosimilar market continues to grow, one question on everyone's mind is: how can we make the most of this opportunity? One strategy that's gaining traction is biosimilar-to-biosimilar s... Source
- Study Reveals Key Predictors of Early Patent Challenges for FDA-Approved Drugsby Insights: DrugPatentWatch - Find Your Next Blockbuster on February 14, 2025 at 11:40 am
The Hidden Factors Behind FDA-Approved Drugs' Patent Challenges As a healthcare professional or a pharmaceutical industry expert, you're likely no stranger to the complex world of drug patents. But have you ever wondered what sets some FDA-approved dru... Source
- The Role of Partnerships in Generic Drug Developmentby Insights: DrugPatentWatch - Find Your Next Blockbuster on February 13, 2025 at 9:12 am
Breaking Down Barriers: The Power of Partnerships in Generic Drug Development As the pharmaceutical industry continues to evolve, one thing is clear: collaboration is key. In the world of generic drug development, partnerships are playing an increasing... Source
- DrugChatter: Does fish oil interact with vascepa?by DrugChatter on February 12, 2025 at 9:10 pm
Does Fish Oil Interact with Vascepa? A Comprehensive Guide As the world becomes increasingly aware of the importance of... https://www.Drugchatter.com/chat/45752/does-fish-oil-interact-with-vascepa/ Source
- How to Manage Generic Drug Development Timelines: Strategies for Successby Insights: DrugPatentWatch - Find Your Next Blockbuster on February 12, 2025 at 9:10 am
The Art of Timing: Mastering Generic Drug Development Timelines As a seasoned professional in the pharmaceutical industry, you know that navigating the complex landscape of generic drug development can be a daunting task. One of the most critical facto... Source
- DrugChatter: How does lipitor affect white wine?by DrugChatter on February 11, 2025 at 4:56 pm
The Impact of Lipitor on White Wine: A Comprehensive Guide As a popular cholesterol-lowering medication, Lipitor (atorvastatin)... https://www.Drugchatter.com/chat/37341/how-does-lipitor-affect-white-wine/ Source
- Fierce Biotech Fundraising Tracker '25: Adcytherix adds $122M; Peptilogics pumps up with $78Mby , , on December 23, 2024 at 12:22 pm
The Fierce Biotech Fundraising Tracker records venture capital rounds of $50 million or more secured by biotechs.
- Fierce Biotech Layoff Tracker 2025: Kezar plots cuts; Ascidian Tx trims teamby , on December 23, 2024 at 11:52 am
As always, if you know of layoffs occurring at a biotech, please reach out to the Fierce Biotech editorial team.
- Announcing DIYbiosphere: an open source project to connect DIYbio related activities worldwideby Jason Bobe on March 17, 2018 at 10:53 am
With significant growth in activities globally, our /local page has strained to keep up and simply is not a great...